Generic pharmaceutical company Lannett Company Inc (NYSE:LCI) stated on Monday that it recorded a net loss of USD7.6m (USD0.20 per share) for its fiscal fourth quarter ended 30 June 2019.
This is an improvement in earnings when compared with a higher net loss of USD11.4m (USD0.30 per share) for the fiscal 2018 fourth quarter.
GAAP net sales of USD133.8m were recorded for its fiscal fourth quarter ended 30 June 2019, down over USD170.9m for the fourth quarter of fiscal 2018.
Research and development (R&D) expenses of USD9.4m were reported for its fiscal fourth quarter ended 30 June 2019, a rise versus R&D of USD8.3m for the fiscal 2018 fourth quarter.
Lannett reports issuance of USD75m convertible senior notes
Meitheal Pharmaceuticals Launches Heparin Sodium Injection, USP in the United States
Xellia Pharmaceuticals Names Baker as Chief Commercial Officer of Xellia North America
Dr. Reddy's Laboratories Launches Fosaprepitant for Injection in the US Market
US FDA grants SunGen Pharma seventh ANDA approval for Fosapreptant
US FDA grants approval to Novitium Pharma's Biovitrum's Orfadin
Sagent Pharmaceuticals gets FDA clearance for Omega manufacturing site
Novadoz Pharmaceuticals awarded FDA clearance for Fosaprepitant and Decitabine generics